UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION~~

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~December~~January 228, ~~2015~~2016

OxySure Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		000-54137		71-0960725
(State or other jurisdiction of incorporation or organization)		(Commission file number)		(IRS Employer Identification No.)

10880 John W. Elliott Drive, Suite ~~600~~ ~~Frisco, TX 75033 (Address of Principal Executive Offices)~~ 600

~~(972) 294-6450 (Registrant’s Telephone Number~~Frisco, ~~Including~~TX ~~Area Code)~~75033

(Address of Principal Executive Offices)

(972) 294-6450

(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

ITEM 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Effective November 30, 2015, the Company changed its name from “OxySure Systems, Inc.” to “OxySure Therapeutics, Inc.” (the “Name Change”) by filing a certificate of amendment (“Certificate of Amendment”) to its Articles of Incorporation with the Secretary of State of the State of Delaware. No other amendments were made to the Company’s Articles of Incorporation. The Certificate of Amendment is attached hereto as Exhibit 3.1 and incorporated herein by reference.

ITEM 7.01

Regulation FD Disclosure.

On ~~December 2~~January 27, ~~2015~~2016, OxySure Therapeutics, Inc. (the “Company”), ~~issued~~the aBoard ~~press~~of ~~release~~Directors ~~announcing~~of the ~~Name~~Company ~~Change.~~and Acertain ~~copy~~stockholders of the ~~press~~Company ~~release~~filed isa letter ~~furnished~~with asthe ~~Exhibit~~office 99of U.1 S. Senator John Cornyn requesting referrals to ~~this~~the ~~report~~Securities and ~~incorporated~~Exchange ~~herein~~Commission byand ~~reference~~other authorities to initiate investigations into certain manipulative short selling, naked short selling or other illegal short selling activities relating to the trading of the Company’s common stock. The Company’s stock is traded on OTCQB under the ticker symbol OXYS. A copy of the letter is filed herewith as Exhibit 99.1.

The ~~information contained~~Company inalso ~~this Item 7.01 of this report is being furnished and shall not be deemed “~~filed” ~~for~~a ~~purposes~~similar ofcomplaint ~~Section 18~~directly ofwith the Securities ~~Exchange~~and ~~Act of 1934, as amended (the “~~Exchange ~~Act”),~~Commission oron ~~otherwise subject to the liabilities~~behalf of ~~that~~the ~~section.~~Company ~~The~~and ~~information~~all inits ~~this Item 7~~stockholders.01 ~~shall~~The ~~not~~Company beis ~~deemed~~seeking ~~incorporated~~full byaccountability ~~reference~~and inimmediate ~~any~~delivery ~~filing under the Securities Act~~ of ~~1933,~~all asOXYS ~~amended,~~shares orsold short ~~the~~over ~~Exchange~~a ~~Act,~~period ~~except~~of asover ~~expressly~~fourteen ~~set forth by specific reference in such filing~~months.

The information contained in this Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

ITEM 9.01

Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No. Description

Exhibit No.		Description of Exhibit

99.1		Letter dated January 26, 2016.

~~3.1 Certificate of Amendment, filed November 30, 2015, to the Company’s Articles of Incorporation~~2

99.1 Press release, dated December 2, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 2, 2015	OxySure Therapeutics, Inc.
Date: January 28, 2016	OxySure Therapeutics, Inc.
	By:	/s/ Julian T. Ross	~~/s/ Julian T. Ross~~
	Name:	Julian T. Ross	~~Julian T. Ross~~
	Title:	Chairman, Chief Executive Officer, President, and Chief Financial Officer	~~Chairman, Chief Executive Officer, President, and Chief Financial Officer~~

Filing Compare · OxySure Therapeutics, Inc.